Belgian companies account for just under a quarter (24%) of the total stock market value of all public biotech companies in Europe.
Johnson & Johnson is re-upping its commitment to addressing health inequities as the pandemic lays bare long-standing divisions.
It’s estimated that 10% to 15% of people with Parkinson’s have a genetic form of the disease and Sanofi Genzyme is backing a new study to help find those people.
More than one-fourth of the world’s diabetes patients live in China—and Novo Nordisk wants to give them a better way to ask questions and get information.
The investment, Sanofi’s first in a private French fund, boosts Rafaèle Tordjman’s efforts to establish Jeito as an emerging force in the European biotech VC scene.
